2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

4:30PM-6:00PM: Abstract Number: 3194

Oral to Subcutaneous Methotrexate Dose-Conversion Strategies in the Treatment of Rheumatoid Arthritis

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy VI: Strategies

4:30PM-6:00PM: Abstract Number: 3230

Perceived Barriers in Care for Arthritis

ARHP IV: Clinical Practice and Patient Care

4:30PM-6:00PM: Abstract Number: 3170

Peripheral Osteoblastogenesis in Rheumatoid Arthritis Is Enhanced after TNF Blocker Treatment, Irrespective of Systemic Inflammation

Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis

4:30PM-6:00PM: Abstract Number: 3196

Predictive Biomarkers for Response or Non-Response to MTX Monotherapy in Early RA

Rheumatoid Arthritis-Small Molecules, Biologics and Gene Therapy VI: Strategies

4:30PM-6:00PM: Abstract Number: 3187

Predictors of Disease Relapse and Recapture of Remission Following Relapse in an Ontario Rheumatoid Arthritis Population

Rheumatoid Arthritis - Clinical Aspects V: Goal = Remission

4:30PM-6:00PM: Abstract Number: 3173

Premature Mortality Due to Fractures in a Population-Based Prospective Cohort Study of 238,673 Older Women and Men

Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis

4:30PM-6:00PM: Abstract Number: 3162

Prevalence of Chronic Comorbidities in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Systemic Lupus Erythematosus: An Analysis of UK Biobank Data

Epidemiology and Public Health IV: Risk Factors and Comorbidities for SLE and Psoriatic Arthritis

4:30PM-6:00PM: Abstract Number: 3161

Rates of Hospitalization for Infection and Related Mortality By Race/Ethnicity and Sex Among Patients with End-Stage Renal Disease Due to Systemic Lupus Erythematosus

Epidemiology and Public Health IV: Risk Factors and Comorbidities for SLE and Psoriatic Arthritis

4:30PM-6:00PM: Abstract Number: 3222

Repeated Administration of Dapirolizumab Pegol (DZP) Appears Safe and Well Tolerated in Patients with Systemic Lupus Erythematosus (SLE) and Is Accompanied By an Improvement in Disease Activity: Results from a Phase 1 Study

Systemic Lupus Erythematosus - Clinical Aspects and Treatment VI: Novel Therapies

4:30PM-6:00PM: Abstract Number: 3234

Roadblocks Perceived By Canadian Dermatologists for Referring Patients with Suspected Psoriatic Arthritis

ARHP IV: Clinical Practice and Patient Care

4:30PM-6:00PM: Abstract Number: 3221

Safety and Efficiency of Low-Dose Interleukin-2 Treatment in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus - Clinical Aspects and Treatment VI: Novel Therapies

4:30PM-6:00PM: Abstract Number: 3224

Salivary IL-1 Alpha and IL-1 Beta Levels Are Associated with Oral Mucosal Activity in Behcet’s Disease

Vasculitis IV

4:30PM-6:00PM: Abstract Number: 3191

Siglec9 Suppresses Arthritis in Collagen-Induced Mice Model and Inhibits M1 Activation of RAW264.7 Macrophages

Rheumatoid Arthritis Animal Models II

4:30PM-6:00PM: Abstract Number: 3228

Sofosbuvir Plus Ribavirin for Hepatitis C Virus Associated Cryoglobulinemia Vasculitis: Vascuvaldic Study

Vasculitis IV

4:30PM-6:00PM: Abstract Number: 3208

Spinal Radiographic Progression in Early Axial Spondyloarthritis: Data from the DESIR Cohort

Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Clinical Aspects, Imaging and Biomarkers

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].